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DOI 10.1016/j.ccr.2011.12.029SUMMARYReversal of promoter DNA hypermethylation and associated gene silencing is an attractive cancer therapy
approach. The DNA methylation inhibitors decitabine and azacitidine are efficacious for hematological
neoplasms at lower, less toxic, doses. Experimentally, high doses induce rapid DNA damage and cytotox-
icity, which do not explain the prolonged time to response observed in patients.We show that transient expo-
sure of cultured and primary leukemic and epithelial tumor cells to clinically relevant nanomolar doses,
without causing immediate cytotoxicity, produce an antitumor ‘‘memory’’ response, including inhibition of
subpopulations of cancer stem-like cells. These effects are accompanied by sustained decreases in ge-
nomewide promoter DNA methylation, gene reexpression, and antitumor changes in key cellular regulatory
pathways. Low-dose decitabine and azacitidine may have broad applicability for cancer management.INTRODUCTION
Decitabine (DAC) and its analog azacitidine (AZA), two major
DNA demethylating agents (Jones and Taylor, 1980), have
recently emerged as potent therapies for the preleukemic hema-
tological disease myelodysplastic syndrome (MDS), and for es-
tablished leukemias (Blum et al., 2007; Cashen et al., 2010;
Issa et al., 2004), leading to approval from the Food and DrugSignificance
The mechanisms underlying clinical efficacies of the DNA me
Understanding how these drugs work would be a pivotal step
these drugs work in myelodysplastic syndrome because low d
exerting cytotoxic effects. We show that nanomolar doses of
effects on both cultured and primary human leukemic and epith
ing, and drug-resistant cell populations. These effects are acc
DNAmethylation and gene expression which affect multiple ke
macologic anticancer strategies.
430 Cancer Cell 21, 430–446, March 20, 2012 ª2012 Elsevier Inc.Administration for patients with MDS (Kantarjian et al., 2006; Sil-
verman et al., 2002). Remarkably, the improved clinical efficacy
and safety profile have emerged only as doses of the drugs,
given either alone (Issa et al., 2004; Kantarjian et al., 2006,
2007) or in combination with histone deacetylase (HDAC) inhib-
itors (Gore et al., 2006), were significantly reduced. Despite the
clinical efficacy observed in hematological neoplasms, these
lower dosing regimens have not been thoroughly tested inthylation inhibitors decitabine and azacitidine are unclear.
in furthering epigenetic therapy. Clinical clues suggest that
oses provide antitumor effects over time rather than acutely
both drugs have, without acute cytotoxic effects, antitumor
elial tumor cells, including themost tumorigenic, self-renew-
ompanied by sustained, genomewide changes in promoter
y regulatory pathways that are high-priority targets for phar-
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have been plagued by extreme toxicities that have probably
confounded the ability to document true clinical responses
(Abele et al., 1987; Momparler et al., 1997). Even for the
successes in hematologic neoplasms, it is still under debate
whether epigenetic effects of the drugs account for all, or even
some, of the therapeutic response (Issa and Kantarjian, 2009).
In a recently completed clinical trial for advanced lung cancer
using a low-dose regimen that has efficacy in MDS, we have
seen some very durable, complete, partial, and stable responses
in a subset of patients who have failed multiple previous chemo-
therapy regimens (Juergens et al., 2011). These results empha-
size the importance of deciphering the mechanisms involved
with therapeutic efficacy of DAC and AZA and understanding
how low, nanomolar doses of DAC and AZA are effective at
inducing sustained antitumor responses.
RESULTS
Transient, Low-Dose DAC Decreases Tumorigenicity
of Cultured Leukemia Cells with Minimal Acute DNA
Damage, Cell Cycle Alterations, or Apoptosis
DAC and AZA were originally designed as nucleoside analogs
that, at high doses, clearly produce DNA damage and cytotox-
icity (Karpf et al., 2001; Palii et al., 2008). However, these effects
may not be the primary mechanisms responsible for the clinical
efficacy in patients with MDS or leukemia. We, thus, first sought
to separate low-dose, from high-dose effects of DAC on cultured
leukemia cells. We used the very low doses, indicated by phar-
macokinetic studies to be in the nanomolar range for DAC (20
to 300 nM) (Cashen et al., 2008; Schrump et al., 2006), to which
tumor cells in responding patients with MDS/AML are most likely
exposed in settings of clinical efficacy. Kasumi-1 cells, an acute
myelogenous leukemia (AML) line with a stem-cell-like pheno-
type characterized by a high fraction of CD34+ early progenitor
cells (Asou et al., 1991) (Figure S1A available online), are known
to be sensitive to cytotoxic effects of high-dose DAC (Berg et al.,
2007). Indeed, daily doses of 500 nM DAC for 3 days produced
50% apoptosis, which reached over 90% by 4 days after drug
withdrawal (Figure S1B), while 10 nM produces little or no cell
death at 3 days in Kasumi-1, KG-1, and KG-1a AML cells and
in histiocytic lymphoma U-937 cells (Figures 1A and S1C). It is
important to note that this lack of early cytotoxicity at 10 nM is
subsequently followed, after drug withdrawal, by sustained rates
of apoptosis, leveling off at 40% for Kasumi-1 and 25% for
KG-1 leukemia cells (Figure S1D). Consistent with these obser-
vations, the 3-day 10 nM DAC exposures produce little cell cycle
changes between mock and treated Kasumi-1 cells at Day 3
(Figure 1B) and 4 and 11 days after drug withdrawal (Figure S1E)
or significant increases in double-strand DNA breaks in CD34+
and CD34 Kasumi-1 cells at Day 3 (Figure 1C). In contrast,
100 nM of cytarabine (Ara-C), a compound structurally similar
to DAC and a standard cytotoxic chemotherapeutic agent
used for AML therapy, causes distinct prolongation of S-phase
(Figure 1B).
Despite the aforementioned lack of acute cytotoxic effects,
the 3-day, 10 nM dose of DAC can fully (for Kasumi-1, KG-1,
and KG-1a cells and partially for U-937 cells) inhibit subsequent
colony formation in methylcellulose assays performed over20 days in drugfree media (Figures 1A and S1C). Similarly,
100 nM DAC produces no initial apoptosis in chronic myeloge-
nous leukemia, K-562 cells, but sharply reduces subsequent
colony formation (Figure S1C). Acute promyelocytic leukemia
NB4 cells are sensitive to both early apoptosis and diminishing
of proliferation at 10 nM DAC (Figure S1C).
It is important to note that these anticloning effects for sensi-
tive cells such as Kasumi-1 are sustained and wane only slowly
after drug removal. First, the 10 nM dose of DAC blunts clono-
genic potential of the cells in repeated methylcellulose colony-
forming assays performed without subsequent drug exposure
over 28 days (Figure S1F). Second, the transient 3-day exposure
of 10 nM also inhibits, in serial methylcellulose replating assays,
colony formation for Kasumi-1 (Figure 1D) and KG-1 (Figure S1G)
cells and markedly decreases this ability for U-937 and K-562
cells (Figure S1G). In contrast, 10 or 100 nM doses of Ara-C
produce much less inhibition of colony growth (Figure 1A).
Finally, 10 nMDAC for 3 days alsomarkedly blunts cloning of Ka-
sumi-1 and KG-1 cells in a 5-week, drugfree, feeder layer assay
that supports long-term culture-initiating cells (LTC-IC) (Fig-
ure 1E). Ara-C, again, fails to reduce LTC-IC (Figure 1E), which
is consistent with the known poor capability of this drug to target
such leukemic cell populations (Guzman et al., 2001).
The ultimate test of tumor initiation for leukemia and solid
tumor cells (Lapidot et al., 1994; Al-Hajj et al., 2003; Li et al.,
2007; O’Brien et al., 2007; Ricci-Vitiani et al., 2007; Schatton
et al., 2008; Singh et al., 2004) is engraftment capability and
tumor growth of the most tumorigenic or more ‘‘stem-like’’ cells
in mice (Jordan et al., 2006). Kasumi-1 has a high percentage of
stem-like CD34+ cells. Only purified CD34+, and not CD34, Ka-
sumi cells are tumorigenic in mice (Figure 1F). Of note, our tran-
sient, low-dose treatment with DAC inhibits colony formation of
both CD34+ and CD34 Kasumi-1 cells (Figure 1G). Most strik-
ingly, a 3-day treatment of Kasumi-1 cells to 10 nM DAC mark-
edly delays, without any drug treatment of recipient animals,
detectable engraftment of Kasumi-1 cells in the peripheral blood
and the bone marrow of NOD/Shi-scid/IL-2Rgnull mice (Figures
1H and 1I) and decreases the percentage of CD34+ leukemic
stem/progenitor cells that do appear in bone marrow (Figure 1J).
Thus, a 10 nM transient DAC exposure markedly inhibits subse-
quent leukemia-initiating CD34+ in vivo.
Low-Dose DAC, without Acute Cytoxicity, Blunts
Clonogenicity of Primary Leukemia Cells but Not
Primary Normal Bone Marrow Cells
Low-dose DAC can produce many of the same effects observed
earlier on primary AML cells without the toxic effects on primary
bone marrow cells. Thus, a 3-day transient 10 nM dose of DAC
markedly blunts the ability of five of six primary samples from
patients with newly diagnosed AML to subsequently clone in
methylcellulose (Figure 2A) without causing early cell apoptosis
or change in cell cycle (Figures 2B and 2C). This same 10 nM
dose of DAC fails to blunt the ability of a normal bone marrow
sample to generate progenitor colonies for multiple marrow line-
ages and did not cause significant apoptosis (Figures 2D and
2E). All of the aforementioned results are consistent with clinical
results for MDS/AML, wherein delayed, robust antitumor res-
ponses can be produced while the normal bone marrow param-
eters are restored.Cancer Cell 21, 430–446, March 20, 2012 ª2012 Elsevier Inc. 431
Figure 1. Low-Dose DAC Treatment Diminishes Self-Renewing and Leukemia-Initiating Capacities in Cultured Leukemia Cells
(A) Apoptosis and methylcellulose colony-forming assays of Kasumi-1 cells after 72 hr daily treatment with DAC or cytarabine (Ara-C). *p < 0.05 compared to
mock by analysis of variance (ANOVA) and Dunnett’s multiple comparison test.
(B) Cell cycle analysis of Kasumi-1 after DAC or Ara-C daily treatment for 72 hr. *p < 0.05 by ANOVA and Bonferroni posttests.
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Solid Tumor Stem-like Cells and Diminish
Tumorigenicity
We next determined doses of DAC/AZA that were acutely
nontoxic to cultured breast cancer cells but that might affect
their tumorigenic properties. We found that transient 3-day
exposure of MCF7 cells to 100 nM DAC at Day 3 of drug treat-
ment or 4 days after drug withdrawal (day 7), or an equivalent
dose of 500 nM AZA at 7 days after drug withdrawal (day 10),
produced little apoptosis (Figure S2A). Similarly, 3 days of expo-
sure to 100 nM DAC or 500 nM AZA led to minimal cell cycle
changes over time (Figure S2B). Significant decreases were
observed for MCF7 cells in anchorage-independent growth in
soft agar, a classic in vitro transformation assay, for both
100 nM DAC and 500 nM AZA (Figure S2C). Similarly, 3-day
treatments with 10 nM DAC (Figure S2D), 100 nM DAC (Fig-
ure 3B), and 500 nM AZA (Figure 3C), followed by subcutaneous
injection into untreated nonobese diabetic (NOD)/SCID mice
(Figure 3A), significantly reduced the size of MCF7 xenografts.
This diminished tumorigenicity persisted in serially transplanted
secondary xenografts (Figures 3A and 3B). An even stronger
decreasewas produced in tumor growth for T-47Dbreast cancer
cells. Growth was also suppressed for HCT116 colon and H2170
lung cancer lines (Figure 3C). Moreover, for clinical relevance, we
tested several short cycles and therapeutic doses of AZA in mice
bearing established xenografts of MDA-MB-231, MCF7, and
T-47D breast cancer cells. In MDA-MB-231 and T-47D xeno-
grafts, the lowest dose of drug led to the largest reduction in
tumor size, whereas in MCF7 xenografts, all doses were compa-
rable (Figure 3D). There were, again, no changes in proliferative
capacity of cells in the treated MCF7 tumors (Figure S2E).
Transient Low Doses of AZA Inhibit Primary Breast
Cancer Stem-like and Self-Renewing Cells
We further investigated the effects of transient, low-dose AZA
treatment on the self-renewal potential of primary cancer cells
isolated from the pleural effusions of four patients with meta-
static breast cancer of the luminal type. These cells were treated
for 3 days with 500 nM AZA, followed by drug withdrawal and
culture in suspension as tumor spheres and serial passaged to
test for self-renewal capacity and stem-like cell activity (Fig-
ure 4A) (McDermott andWicha, 2010; Korkaya et al., 2009; Char-
afe-Jauffret et al., 2009; Dontu et al., 2003; Ginestier et al., 2007;(C) gH2AX foci formation in CD34+ and CD34 Kasumi-1 cells after 72 hr DAC trea
calculated as fold change relative to that of mock treatment. ns, not statistically
(D) Serial methylcellulose replating assays of Kasumi-1 after 72 hr daily treatmen
*p < 0.01 compared to mock by ANOVA and Bonferroni posttests.
(E) Long-term culture-initiating cell assay of Kasumi-1 and KG-1 AML cells after
Whitney test.
(F) Engraftment assay in NOD/Shi-scid/IL-2Rgnull mice of CD34+ versus CD34 K
and bone marrow (BM) of transplant mice 4 to 5 months posttransplantation. No
(G) Methylcellulose colony-forming assay of CD34+ and CD34 Kasumi-1 cells a
ANOVA with Bonferroni posttests.
(H and I) Engraftment assay in NOD/Shi-scid/IL-2Rgnull mice of Kasumi-1 cells pre
peripheral blood (H) and in bone marrow (I) is shown. p values were calculated b
(J) Percentage of CD34+ and CD34 Kasumi-1 AML cells after daily treatment o
*p < 0.05 by Mann-Whitney test. All error bars represent standard errors.
See also Figure S1.Liu et al., 2006). There was dramatic inhibition of primary sphere
formation and an inhibitory effect that persisted through two
subsequent serial passages (Figure 4B), while spheres from
mock-treated cells showed a trend toward enrichment from
passage two to passage three (see patients #103, #PE1, and
#105; Figure 4B). Thus, 3 days of exposure to low-dose AZA
reduces the self-renewal capacity of primary breast cancer cells
consistent with our observation that AZA treatment decreases
a self-renewing population in breast cancer cell lines. Aldehyde
dehydrogenase (ALDH1) and CD44+/CD24lo have emerged as
markers for cancer stem-like cells in breast and are predictive
for metastasis and poor prognosis (Al-Hajj et al., 2003; Ginestier
et al., 2007). We find, in agreement with others, that the MCF7
breast cancer line has 0.5% ALDH1+ cells (Charafe-Jauffret
et al., 2009) and T47Ds contain 5% CD44+/CD24lo (data not
shown). A 3-day treatment with 500 nM AZA and 10 nM DAC
significantly reduced CD44+/ALDH1+ cells for up to 17 days after
drug withdrawal (Figure 4C), with no changes observed in the
larger CD44+/ALDH1- cell population (data not shown). Similar
results were observed for 100 nM DAC (data not shown). For
T-47D cells, a similar 3-day treatment with 500 nM AZA reduced
the CD44+/CD24lo population for up to 11 days after drug with-
drawal (Figure 4C). Likewise, 3 days of 500 nM AZA decreased
the CD44+/CD24lo population in mammospheres from patient
#105 (Figure 4C).
Last, we tested the effects of low-dose AZA on primary tumor
tissue from breast cancer patients. Therapeutic administration of
AZA (0.5 mg/kg) significantly inhibited the growth of three prees-
tablished, patient-derived tumors, engrafted orthotopically into
immunodeficient mice (Figure 4D) (DeRose et al., 2011)
Low-DoseDAC Inhibits GenePromoter DNAMethylation
and Causes Re-Expression of Hypermethylated Genes
The ability of transient low doses of DAC to sustain long-term
antitumor effects is associated, at least temporally, with the re-
tained ability of this drug to target DNA methylation processes
and alter gene expression, in each of the cell types under study.
DAC and AZA, after their incorporation into DNA, are known to
bind to and block the catalytic site of DNA methyltransferases
(DNMTs). This covalent binding effectively traps DNMTs as
adducts to DNA (Ferguson et al., 1997; Gabbara and Bhagwat,
1995; Santi et al., 1984). Additionally, DAC and AZA can trigger
proteosomal degradation of the maintenance DNMT, DNMT1tment. For each treatment, cells containing more than 15 foci are counted and
significant by ANOVA and Bonferroni posttests.
t of DAC or Ara-C. Equal numbers of viable cells were plated for each plating.
72 hr daily treatment of DAC or Ara-C. *p < 0.05 compared to mock by Mann-
asumi-1 cells. Human CD45+ cells were analyzed in the peripheral blood (PB)
engraftment was observed in any mice receiving CD34 cells.
fter 72 hr daily treatment with 10 nM DAC. *p < 0.001, compared to mock, by
treated daily with 10 nM DAC for 72 hr. Percentage of human leukemia cells in
y Mann-Whitney test.
f 10 nM DAC for 72 hr in vitro and after engraftment in mouse bone marrow.
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Figure 2. DAC at Non-Acutely Cytotoxic Doses Blunts Clonogenicity of Primary Human Leukemia Cells but Not Normal Bone Marrow Cells
(A) Methylcellulose colony-forming assay of bone marrow mononuclear cells from six patients with newly diagnosed AML after 72 hr daily DAC treatment and
4-day recovery period in vitro. Images and quantifications of colonies are shown in upper and lower panels, respectively. *p < 0.05 compared to mock by ANOVA
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Antitumor Effect of Low-Dose Demethylating Agents(Ghoshal et al., 2005). Three days of 10 nM DAC leads to early
depletion of DNMT1 protein in Kasumi-1, KG-1, and KG-1a
leukemia cells, and 100 nM gives a similar effect in three different
breast cancer lines (Figure 5A). Despite these similar effects on
early depletion of DNMT1 in all tested cell lines, the duration of
the effect does not correlate with the later phenotypic conse-
quences of drug treatment described earlier. Thus, while
DNMT1 protein levels quickly recover in most of the lines,
DNMT1 depletion lasts for at least 25 days after drug withdrawal
in Kasumi-1 cells, although the phenotypic responses of these
cells are similar to those of KG-1 cells (Figure 5A). Thus, transient
or sustained inhibition of DNMT1 protein expression by 3 days of
DAC treatment accompanies prolonged, subsequent, antitumor
effects.
In keeping with the early depletion of DNMT1 protein levels,
low-dose DAC causes demethylation and reexpression of DNA
hypermethylated and epigenetically silenced genes. A 3-day
exposure to 10 nM DAC produces, in both CD34+ and CD34
Kasumi-1 cells, significant demethylation of the completely
methylated and silenced tumor suppressors CDKN2B and
CDH1 (Figures 5B and 5C). One particularly important finding
with respect to the cellular phenotypes observed involves the
expression of some initially silenced genes. In the treatment
schema used wherein cells are not acutely killed, we see in
both Kasumi-1 and KG-1a cells increased transcription long
after drug withdrawal. This is exemplified by CDKN2B, for which
the peak expression is reached at Day 14, or 11 days after cessa-
tion of drug administration (Figure 5D).
It is important to note that these methylation effects are seen
across the genome in analyses of DNA methylation by using
the Methylation 27 BeadChip for cultured cells and the more
probe-dense HumanMethylation450 BeadChip 450K for the
treated 1107 and 1307 primary leukemia cells (Figure 2A). DAC
(10 nM) for 72 hr causes a distinct decrease in methylation for
essentially all probes and genes with high initial levels of DNA
methylation in Kasumi-1 cells (Figures 6A and 6B),many of which
are also heavily methylated in DNA from primary AML samples
(Figure S3A). The decreases can be seen in promoter regions
of both CpG island- and non-CpG island-containing genes (Fig-
ure 6C). This dose similarly reduces global methylation of highly
methylated genes in KG-1 and KG-1a cells, as does 100 nM in
breast cancer MCF7 cells (Figure S3B). Treatment of a primary
leukemia sample (PL6347) with 10 nM DAC, after proliferation
stimulation with cytokines, similarly causes decreases in gene
promoter region DNAmethylation (Figures 6B and S3B). Virtually
identical results have been seen for primary, treated leukemiaand Dunnett’s multiple comparison test. Scale bar, 500 mm. #1307 and #29, AML
#9, secondary AML; #20, AML FAB M5.
(B) Annexin V apoptosis assay of one representative AML patient sample (#1307)
harvested for analysis at the end of 72 hr drug treatment (Day 3) and 6 days after
posttests.
(C) Cell cycle analysis on one representative AML patient sample (#1307) was pe
propidium iodide staining. ns, not statistically significant by ANOVA with Bonferr
(D) Methylcellulose colony-forming assays of human normal bone marrow mono
colony-forming unit erythroid; BFU-E, burst-forming unit erythroid; CFU-GM, co
granulocyte, erythrocyte, macrophage, megakaryocyte. ns, not statistically signi
(E) Annexin V apoptosis assay in one representative bone marrow sample (BM #
propidium iodide, and percentage of cells relative to total cells is shown in eachsamples 1107 and 1307 using the 450K platform (data not
shown).
The aforementioned genomic promoter demethylation
induced by low-dose DAC is accompanied by widespread
increases in gene expression (scatter plot for Kasumi-1 cells;
Figures S3C and S3D). In fact, up to 50% of genes whose
expression increase after transient low dose exposure remain
increased for up to 14 days (Figure S3E). Among such genes
are those having decreases in their cancer-specific promoter hy-
permethylation after drug treatment, such as CDKN2B in Ka-
sumi-1 (Figure 5C) and KG-1a AML cells (Figure S5), CDKN2A
in KG-1a cells, and six hypermethylated genes (Figure 6D)
studied by Lubbert and colleagues (Flotho et al., 2009), or our
lab, in Kasumi-1 cells, DAPK1, CDKN1C (also known as
p57KIP2),HOXA9,HGF,DLK1, andRAB13. All these eight genes
have increased expression by Day 3 of low-dose decitabine
treatment, and seven have sustained increases at least
11 days after treatment cessation (Figure 6D).
Transient Low Doses of DAC and AZA Induce Sustained
Alterations in Major Cancer Cell Signaling Pathways
Cancer is driven by alterations of gene function in key cellular
pathways (Hanahan and Weinberg, 2011). We find, using
Metacore analyses of gene expression, changes in many key
antitumor pathways (Figures 7A, 7B, S4A, and S4B; Tables S1
and S2).
Changes in gene expression, which would block cell prolifera-
tion and decrease tumor self-renewing populations, were often
correlated with increases in expression of more than one cy-
clin-dependent kinase inhibitors (CDKN2B, CDKN2A, CDKN1A)
and were associated with CpG island DNA demethylation for
CDKN2B in leukemia cells (Figures 7A and 7B). The upregulation
of p14ARF, CDKN2A, CDKN1A, and other key hypermethylated
pathway genes, such as SLIT2 and ROBO3, were validated in
cultured leukemia cells (Figure 8A). The FOXM1-polo-kinase
(PLK)-Aurora kinase pathway would be predicted to be downre-
gulated secondary to the aforementioned gene increases (Koo
et al., 2012). We observed this in both cultured (KG-1a AML)
and primary leukemia cells (#1107 in Figure 2A) and in primary
breast cancer mammosphere samples (#103 and #104 in Fig-
ure 4A; Figure 7B). In each case, CDKN1A expression was
increased and could be linked to DNA demethylation in a DNA
methylated region (Figure 7C) just upstream from a nonhyperme-
thylated CpG island. This pathway, required for cells to enter and
perform cell division and to maintain DNA damage-triggered cell
cycle check points, is increased in tumors with poor prognosiswith FLT3-ITD mutation; #1107, AML FAB M2; #30, AML with mutated NPM1;
after 72 hr daily DAC treatment in vitro. Bone marrow mononuclear cells were
drug removal (Day 9). ns, not statistically significant by ANOVA with Bonferroni
rformed 4 days after drug removal (Day 7) with DNA content measured using
oni posttests.
nuclear cells (BM #1 and #2) after 72 hr daily DAC treatment in vitro. CFU-E,
lony-forming unit granulocyte, macrophage; CFU-GEMM, colony-forming unit
ficant by ANOVA with Bonferroni posttests.
1) after DAC treatment in vitro. Cells were double-stained with Annexin-V and
quadrant. All error bars represent standard errors.
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Figure 3. DAC and AZA at Noncytotoxic Doses Decrease Tumorigenicity in Mouse Tumor Xenografts
(A) Schematic outline of xenograft tumorigenicity assay in NOD/SCIDmice for MCF7 (breast), T-47D (breast), HCT116 (colon), and H2170 (lung) cancer cells after
7- to 14-day recovery period after 100 nM DAC or 500 nM AZA daily treatment for 72 hr.
(B) Primary and secondary xenograft assays of MCF7 cells pretreated with 100 nM DAC. Equal numbers of viable cells were injected in each transplantation.
p value is calculated by ANOVA. n = 6 for each treatment group.
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Antitumor Effect of Low-Dose Demethylating Agentsand has been linked to progenitor cell renewal and increased
cellular invasion, motility, and metastatic potential (Koo et al.,
2012; Raychaudhuri and Park, 2011). Loss of G2M cell cycle
checkpoint control and the downregulation of FOXM1, aurora
kinases, polo kinases, CHK1, CHK2, and MYT1 represent
proteins currently targeted by the pharmaceutical industry to
induce cancer cell apoptosis and/or sensitization to cytotoxic
drugs (Carrassa and Damia, 2011; Merry et al., 2010). In bone
marrow samples from two leukemia patients who responded
to DAC treatment in a clinical trial, sustained DNA demethylation
and increased expression of CDKN2B is detected at early time
points before reduction of the leukemic tumor clone and coinci-
dent with decreases in FOXM1 RNA (Figures 8B and 8C).
We also saw decreased AKT mRNA, and downregulation of
key regulatory genes, TWIST, SLUG, and SNAIL (Hanahan and
Weinberg, 2011), which activate epithelial to mesenchymal tran-
sition (EMT) (Figure 7A). EMT has been closely linked to stem-like
populations in breast cancer and we observe down regulation of
EMT genes in treated, self-renewing primary mammosphere
cells from patients 103 and 104 (Figure 4A; Table S2). Correlative
studies in the laboratory reveal decreased phosphorylation of
AKT in cultured MCF7 breast cancer cells (Figure 8D).
In the self-renewing, primary mammosphere cultures, we saw
changes predictive of diminished cell motility, invasiveness,
induction of angiogenesis, and metastatic potential including
decreased mRNA expression for genes encoding the integrins,
metalloproteinases, and the key cytoskeletal remodeling protein
ezrin (Figure S4A; Table S2). These genes can be overexpressed
in breast cancer, and their downregulation is matched by upre-
gulation of mRNA for genes that suppress these cell processes,
such as the often hypermethylated tissue inhibitors of metallo-
proteinases (TIMPs), thrombospondin, and the complement
receptor, C5AR (Table S2). It is important to note that breast
cancer sample PE1, after 3-day treatment with 500 nM AZA,
appears less invasive and forms a more compact sphere in ma-
trigel (Figure 8E).
Finally, both cultured and primary cells harbored gene expres-
sion changes that predict cell maturation events. Kasumi-1 AML
and primary AML sample 1107 had decreased expression of the
G-CSF receptor and of the c-myc gene and increased expres-
sion, with decreased DNA methylation of the transcription
region, for the transcription factor RARA (Figures 8A and S5).
Coordinately, myeloid commitment at the progenitor cell level
was indicated by DNA demethylation and increased expression
of the normally methylated early myeloid lineage genes, LYZ and
ELANE (Figures S4B and S5; and Table S1); increases in CD13
(Figure S4B), a marker of cells with bipotential maturation to
erythroid and granulocyte cells (Chen et al., 2007); and mature
granulocyte formation (Levy et al., 1990) by increased p47-
phox, p67-phox, and Gp91-phox (Figure S4B; Table S1). All of
these changes were observed both in DAC-treated total AML
cells and tumorigenic CD34+ cells from Kasumi-1 AML (Fig-(C) Primary xenograft assays of MCF7, T-47D, HCT116, and H2170 cells pretrea
ment group.
(D) AZA treatment of mice with pre-established MDA-MD-231, MCF7, or T-47D br
significance determined by two-way ANOVA (p < 0.05). All error bars represent s
See also Figure S2.ure S4B). Also, increased TGF-beta signaling was observed,
and this is known to promote maturation and inhibition of
leukemic progenitor cell renewal (Figure 7A) (Lewis et al., 2001;
Watabe andMiyazono, 2009). Concomitantly, there is decreased
canonical WNT pathway signaling associated with reduced
methylation; increased expression of WIF1 (Figures 7A and
S5), a Wnt antagonist gene; and downstream decrease in
expression of c-myc (Figure 7A), a canonical target for Wnt
pathway activation (He et al., 1998). Of note, we validatedmyelo-
cyte differentiation by flow cytometric analysis of a surface
marker for mature granulocyte, CD11b, in a treated primary
AML sample 29 (Figure 8F). Sustained increase of cytokeratin
18 (CK18) in DAC- or AZA-treatedMCF7 cells, as well as in tumor
xenografts from mice treated for 6 weeks with AZA (Figure 8G),
was also observed. CK18 expression reflects maturation of
breast luminal cells, and loss of CK18 is associated with poor
prognosis in breast cancer patients (Woelfle et al., 2004).
DISCUSSION
Our present studies indicate that treatment of cancer cells with
clinically relevant low doses of DAC and AZA can exert sustained
changes in gene expression and critical signaling pathways
involved in tumorigenesis without inducing immediate cytotoxic
effects such as DNA damage, apoptosis, and cell cycle arrest.
Our preclinical use of transient 3-day exposure to such doses
ex vivo produces a ‘‘memory’’ type of antitumor response in
mice bearing transplanted tumor xenografts, which may
resemble the prolonged time to response seen in patients with
hematologic neoplasms (Kantarjian et al., 2006; Oki et al.,
2008; Silverman et al., 2002). In patient tumors and mammo-
spheres, the antitumor response occurred more quickly and
appeared to be more sensitive to AZA than that observed for
cancer-cell-line-generated tumors. This may be explained by
the fact that the human tumors were exposed to a longer, more
sustained treatment and that primary tissues may be initially
more sensitive to AZA. All of these aforementioned dynamics
after transient drug exposure are accompanied by genomewide,
prolonged gene promoter DNA demethylation and sustained
increases in gene expression, some of which occur for key tumor
suppressor genes in leukemia and breast cancer cells.
There are several reasons to suggest that at least one key
mechanism underlying the antitumor responses we demon-
strate may involve a resetting of abnormal epigenetic states in
treated cancer cells. First, we have achieved a sustained
change in the pattern of gene expression without changing
primary DNA sequence. Second, as defined for an epigenetic
change, these sustained changes persist for significant periods
of time after a transient, subsequently withdrawn, signal (i.e., in
this case, drug treatment). Third, altered expression patterns
are accompanied by antitumor effects. It is important to note
that we probably have brought out these aspects of DAC andted with 500 nM AZA. p value is calculated by ANOVA. n = 10 for each treat-
east tumors. Tumor volumes are measured at the end of each cycle. *Statistical
tandard errors.
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Figure 4. Low-Dose DAC and AZA Decrease Self-Renewal and Tumorigenesis in Primary Breast Cancer Tissue from Patients
(A) Tumor sphere assays of primary breast cancer cells from pleural effusions after 500 nM AZA daily treatment for 3 days in vitro. Images and quantifications of
tumor spheres are shown in upper and lower panels, respectively. Scale bars, 500 mm.
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Antitumor Effect of Low-Dose Demethylating AgentsAZA treatment by using doses that do not acutely kill cells and,
thus, allow the sustained alterations in both gene expression
patterns and appearance of, to our knowledge, a new pheno-
type to emerge. Of note, these changes include antitumor
events in multiple key pathways, such as apoptosis, increased
lineage commitment, downregulation of cell cycling, and
others, which continue well after drug removal. Reprogramming
might, then, be considered a very desirable type of targeted
therapy that can blunt multiple tumor signaling pathways
simultaneously.
Perhaps one of the most striking effects observed in our study
concerns the fact that nanomolar doses of both DAC and AZA
appear to target, in both cell lines and primary samples of
leukemia and breast cancers, self-renewing and/or tumorigenic
cell subpopulations. This involves stem-like CD34+ cells in
leukemia and CD44+/ALDH1+, CD44+/CD24LO, and mammo-
sphere-forming cells in breast cancer. These findings should
be considered in the context that one of the most important
problems in cancer therapy is the failure of most therapies to
target the subpopulations that are most responsible for sus-
tained tumor cell renewal (Jordan et al., 2006). Our findings
suggest that the often prolonged time course to response in
patients with myelodysplasia or frank AML might involve
a progressive exhaustion of cell populations. This hypothesis
is supported by recent reports that depleting DNMT1, by non-
pharmacologic means, in normal mouse hematopoietic and
human epithelial cells blocks self-renewal and proper cell matu-
ration, leading to cellular depletion of progenitor cells (Bro¨ske
et al., 2009; Sen et al., 2010; Trowbridge et al., 2009). DAC
and AZA do deplete DNMT1 in leukemia and breast cancer cells
for variable time periods after transient exposure (Figure 4A).
However, the mechanisms underlying our pharmacologically
induced responses are certainly more complex since both
DAC and AZA inhibit the catalytic sites of DNMT3a and DNMT3b
as well. Also, all the DNMTs assuredly participate in complex
protein interactions where they may exert scaffolding functions
with effects on other chromatin regulatory features (Robertson
et al., 2000; Rountree et al., 2000). They also, experimentally,
have effects for repressing gene expression that may not require
their directly catalyzing DNAmethylation (Bachman et al., 2001).
This complexity may actually give DAC and AZA an important
advantage in treating cancer cells where they may target all of
these functions and their role in governing the epigenetic aber-
rancies present in cancer. If so, the activities we find for low
nanomolar doses may be very important in rendering these
drugs as gold standards for the development of agents to target
DNA methylation and other epigenetic abnormalities as an anti-
cancer strategy to inhibit the most tumorigenic subpopulations
of cells.
In summary, our findings havemuch relevance for strategies to
use DAC and AZA more widely for the management of cancer.(B) Serial passages of tumor spheres formed by primary breast cancer cells after th
passage. The data show a sustained decrease in self-renewal capacity of tumor
(C) Flow cytometric analyses of CD44+/ALDH+ in MCF7 cells, CD44+/CD24lo ce
treatment for 3 days and subsequent drug removal. Statistical significance was
(D) In vivo AZA treatment of immunodeficient mice bearing orthotopically transp
istered intraperitoneally 5 days/week. All error bars represent standard errors.These drugs are already making an impact for patients with
hematological malignancies. Our findings now suggest ways
and biomarkers that might be used to predict and/or monitor
clinical efficacy. The similar ‘‘memory’’ type of responses we
find for primary and cultured breast cancer cells, and the key
pathway changes seen, indicate that the treatment of many
cancers may be considered and with doses that will be not
only efficacious but also minimally toxic to patients. Such possi-
bilities are emerging in our recently completed trial, sponsored
by Lung Cancer SPORE and Stand Up to Cancer (SU2C), for
patients with advanced non-small-cell lung carcinoma (Juergens
et al., 2011). SU2C trials in breast cancer have now begun that
might be well informed by the preclinical studies we now report.
Moreover, it is especially appealing to consider that DAC and
AZA might sensitize tumor cells to other drugs, as is suggested
by Juergens et al. (2011), that target the oncogenic pathways
we have shown to be altered and allow use of reduced, less
toxic, doses for these other agents.
EXPERIMENTAL PROCEDURES
Methylcellulose Colony-Forming Assay and Serial Replating Assay
After a 3-day drug treatment, equal numbers of viable cells were plated in trip-
licate on to MethoCult H4434 Classic or MethoCult H4435 Enriched (StemCell
Technologies, Vancouver, British Columbia, Canada). Colonies containing
more than 40 cells were quantified at 10-16 days under an inverted micro-
scope. For serial replating assays, equal numbers of viable cells from the first
plating were plated in triplicate in the second plating. Colonies were again
scored after 16-21 days.
Long-Term Culture-Initiating Cell Assay
After a 3-day drug treatment, equal numbers of viable leukemia cells (trypan
blue negative) were plated on to a feeder layer of irradiated M2-10B4 mouse
fibroblasts (StemCell Technologies) and maintained via biweekly one-half
medium changes inMyeloCult H5100 according to themanufacturer’s instruc-
tions (StemCell Technologies). After 5 weeks, cells were harvested and plated
on to MethoCult H4435 Enriched (StemCell Technologies), and colonies were
counted after 14-18 days.
Immunophenotypic Staining and Fluorescence-Activated
Cell Sorting
Human anti-CD34-FITC, anti-CD34-APC, anti-CD38-PE, anti-CD33-APC,
anti-CD15-FITC, anti-CD14-PE, anti-CD11b-APC, anti-CD45-perCP, anti-
CD45-APC, anti-CD44-APC, anti-CD24-PE, and corresponding iso-
type controls were obtained from BD Biosciences, San Jose, CA, USA. The
ALDEFLUOR Assay kit (StemCell Technologies) was used to identify cells
expressing high levels of aldehyde dehydrogenase (ALDH). Cells were stained
according to the manufacturer’s instructions and analyzed on a FACSCalibur
Flow Cytometer (BD Biosciences) using BD CellQuest Pro v.5.2 (BD Biosci-
ences). For sorting, CD34 cells with upper or lower 10% fluorescent intensity
were collected (FACSVantage Cell sorter or BD FACSAria II cell sorter; BD
Biosciences).
Leukemia Engraftment Assay
Cells were tail vein injected into sublethally irradiated (3.0 cG) female NOD/Shi-
scid/IL-2Rgnull mice 6-8 weeks of age. Peripheral blood was sampled everye initial 3-day AZA treatment. Equal numbers of viable cells were plated in each
spheres.
lls in T-47D, and primary breast cancer sample #105 after AZA or DAC daily
determined via two-way ANOVA.
lanted primary breast cancer cells from patients. AZA (0.5 mg/kg) was admin-
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Figure 5. Low-Dose DAC Inhibits Gene Promoter DNA Methylation and Causes Sustained Re-expression of Hypermethylated Genes
(A) Western blot of DNMT1 expression levels in human leukemia cells (Kasumi-1, KG-1a, and KG-1) and breast cancer cells (MCF7, MDA-MB-231, and T-47D)
after 72 hr daily treatment of 10 nM (leukemia) or 100 nM (breast cancer) DAC.
(B) Methylation-specific PCR (MSP) analyses of gene promoter DNA methylation in unsorted, CD34+, and CD34 Kasumi-1 cells before DAC treatment.
U, unmethylated sequence amplifications; M, methylated sequence amplifications; IVD, in vitro methylated DNA; NL, normal lymphocyte DNA.
(C) MSP analyses of CDKN2B and CDH1 promoters in CD34+ and CD34 Kasumi-1 cells at 24, 48, and 72 hr of DAC treatment.
(D) Quantitative real-time PCR analyses ofCDKN2B gene expression over time in Kasumi-1 and KG-1a cells after 72 hr daily treatment of 10 nMDAC. Expression
levels are adjusted to GAPDH for each sample and graphed as fold changes relative to mock. All error bars represent standard errors.
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Figure 6. Genome-wide Methylation and Expression Analyses after Short-Term Exposure to Low-Dose DAC
(A) Histogram of Infinium results for Kasumi-1 methylation profiles after daily DAC or ARA-C treatment for 72 hr. y axis, frequency of probes; x axis, CpG probe
beta scores (lowest to highest = increasing DNA methylation).
(B) Heat map composed of minimal variation beta probes located at 1,000 to +200 bp surrounding transcription start site (5,500 genes). Blue and orange
colors on the left denote non-CpG and CpG island promoters, respectively. PL6347, PL1, PL2, PL4, PL5 are the primary leukemia samples. PL6347+DAC:
primary leukemia after 72 hr 10 nM DAC treatment. mock and mock (rep), untreated Kasumi-1 cells and its replicate. Ara-C, Kasumi-1 cells treated with 100 nM
Ara-C daily for 72 hr. TSA, Kasumi-1 cells treated with 300 nM trichostatin A for 9 hr. DAC (day 3, day 3 rep, day 7, day 14, day 21, day 28), Kasumi-1 cells
harvested at various time points after 72 hr daily treatment of 10 nM DAC.
(C) Box plots showing beta value changes over time in CpG island (upper panel) and non-CpG island gene promoters (lower panel) in Kasumi-1 cells after 72 hr
daily treatment of 10 nM DAC. Ara-C, 100 nM AraC treatment for 72 hr. TSA, 300 nM TSA treatment for 9 hr.
(D) Left panel shows beta value changes after 72 hr, 10 nM DAC treatment for six genes in Kasumi-1 with basal beta values R 0.5. Right panel shows corre-
sponding Agilent expression changes normalized to Day 0. Gray horizontal lines: bottom to top, no change (log2 scale = 0), 1.4-fold (0.5), and 2.0-fold (1.0).
See also Figure S3.
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Figure 7. Metacore Pathway Analyses of Agilent Expression Changes after DAC or AZA Treatment
(A) Key pathways and/or master genes, shown here for studies in cultured cells. Genes in black type indicate genes with expression changes not directly linked to
promoter DNA methylation. Genes in red type indicate genes with basal promoter hypermethylation, drug-induced demethylation, and corresponding increases
in expression. Superscript 1, 2, and 3 by genes or pathways indicate, respectively, Kasumi-1 AML cells, KG-1a AML cells, and MCF7 breast cancer cells with
expression changes concordant in the indicated cell line.
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Engraftment was determined by immunophenotypic staining using human
anti-CD45-perCP and anti-CD34-APC (BD Biosciences).
Solid Tumor Xenograft Tumorigenicity Assay
MCF7, T-47D, HCT116, and H2170 cells were pretreated with 100 nM decita-
bine, 500 nM azacytidine, or PBS (Mock) for 72 hr, followed by another
4-7 days in culture without drug. Harvested cells were injected (1 3 106)
subcutaneously into both flanks of 4- to 6-week-old NOD/SCID mice. Female
mice receiving MCF7 cells were implanted with estrogen pellets (0.72 mg/
60 days; Innovative Research of America, Sarasota, FL, USA). Secondary
xenografts were generated by collagenase dissociation of primary MCF7
tumors at 8 weeks, followed by reinjection of 1 3 106 viable cells into mice.
Therapeutic Administration of AZA to NOD-SCID Mice
with Pre-established Tumors
Mice with preestablished MDA-MB-231, MCF7, or T-47D xenotumors
(0.3–0.5 cm) received subcutaneous daily saline (mock) or azacitidine injec-
tions (2, 1, 0.5, 0.25, or 0.125 mg/kg) for 8 days over a 14-day period per
cycle, as outlined in Figure 2D. Five mice (10 tumors) were used per treatment
group.
For xenograft experiments using cell lines, tumors were measured weekly
and volume was calculated as 0.5 3 (L 3 W2)(mm3). Protocols for all animal
experiments conducted at Johns Hopkins were approved by the John Hopkins
University Animal Care and Use Committee and guidelines were strictly
enforced. Experiments using human tumor xenografts and conducted at the
Huntsman Cancer Institute were reviewed and approved by the University of
Utah Institutional Animal Care and Use Committee.
In Vitro Culture of Primary Human Leukemia and Normal
Bone Marrow Cells
Frozen bone marrow mononuclear cells from patients with freshly diagnosed
acute myelgenous leukemia (#1107 and #1307) or healthy controls (BM #1
and #2) were thawed and cultured in Poietics HPGM (Lonza, Inc., Walkersville,
MD, USA) supplemented with multiple cytokines described in the Supple-
mental Experimental Procedures. Provision of all primary bone marrow and
leukemia samples was through protocols approved by the institutional review
boards (IRBs) at the University of Maryland School of Medicine, The Johns
Hopkins Medical Institutions, and The University of Texas M.D. Anderson
Cancer Center.
Tumor Sphere Assays of Primary Breast Cancer Cells
Malignant plueral effusions were collected under an IRB-approved protocol at
the Johns Hopkins Medical Institutions from women with metastatic breast
cancer undergoing thoracentesis as part of clinical care and who provided
a written consent for use of leftover fluid. The fluid was enriched for malignant
epithelial cells via centrifugation and lysing of red blood cells. Tumorspheres
were maintained on ultralow adherent plates (Corning Inc., Lowell, MA, USA)
in MammoCult (StemCell Technologies) or MCF10A media. (See the Supple-
mental Experimental Procedures for details.) Tumorspheres were treated daily
for 3 days with 500 nM AZA and were cultured 4 more days after drug
withdrawal. Primary spheres were counted and digested with 0.05% trypsin
(Invitrogen, Carlsbad, CA, USA) into single cells. Equal numbers of live cells
were plated in ultralow attachment plates to generate the second spheres.
Again, spheres were counted on Day 7 and digested to generate the third
spheres.(B) An example of pathway diagram summarizes gene changes for cultured and p
or AZA. Events depicted illustrate key expression increases in cyclin-dependen
decreased activity of the FOXM1 pathway and all of the decreases shown earlier
and including the oncogene Skp2.
(C) Analyses of DNA methylation by HumanMethylation450 BeadChip for multip
heavily methylated (two normal bone marrow samples) region 50 to the unmethyla
arrow), is distinctly demethylated after 10 nMDAC treatment in #1107 primary AM
#1307 AML cells, where CDKN1A expression is not increased and the pathway
See also Figure S4 and Tables S1 and S2Global Gene Expression and Methylation Analysis
Gene expression profiles were analyzed, for queried cells, with Agilent Human
43 44K expression arrays (Agilent Technologies, Santa Clara, CA, USA. Global
methylation analysis was performed with the Illumina Infinium Human Methyl-
ation27 BeadChip or HumanMethylation450 BeadChip (Illumina, Inc., San
Diego, CA, USA). Data were processed using R and BioConductor.
Metacore Pathway Analysis
All probes from the Agilent Human 43 44K expression arrays with a change of
at least .5 (log2 scale) up or down at any of the investigated time points were
selected for further analysis and used as input for the Metacore (GeneGo,
Inc.) pathway analysis. Details are described in the Supplemental Experi-
mental Procedures.
ACCESSION NUMBERS
All microarray data are deposited in the GEO database under accession
number GSE20945.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
1016/j.ccr.2011.12.029.
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Figure 8. Validation of Changes in Multiple Signaling Pathways after DAC or AZA Treatment
(A) Quantitative real-time PCR verification for selected genes with expression changes indicated by the Metacore analyses. *p < 0.05 determined by ANOVA and
Bonferroni posttests.
(B) Quantitative real-time PCR analyses of gene expression changes in bone marrow samples taken from patients #1 (partial responder with AML) and #2
(complete responder with CMML) at pretreatment and various time points during or after administration of DAC (20 mg/m2 IV over 1 hr daily 3 5 days every
4 weeks). mRNA levels of two genes,CDKN2B and FOXM1, at each time point were plotted relative to the baseline level after adjusted by a control housekeeping
gene, GAPDH.
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